Reviewed November 16, 2026

Abridge

Private
abridge.com

Clinical documentation AI

Company overview

Revenue
~$100M ARR
May 2025 · Estimate
Reference valuation
$5.3B
Series E reference · Jun 2025
Primary customer
Clinicians[1]
Commercial model
Enterprise subscriptions[1]

Revenue is an independently estimated measure. The valuation is a dated transaction reference, not a current appraisal.[1]

Revenue history

Revenue

ARR · USD

+67%

May 2025 vs. Dec 2024 · calculated change; not annualized

$0$100M$200MDec 2024May 2025
Revenue observations and evidence
PeriodUSDEvidence
$60MEstimate
$100MEstimate

Sacra · company research and financial history ↗

ARR observations are point-in-time measures, not completed annual revenue.

Points show dated observations at equal spacing; intervening performance is not measured.

Products, customers & revenue model

ProductCustomerCommercial model
Clinical documentation[1]Clinicians

Enterprise subscriptions

Health-system deployment[1]Hospitals and care networks

Organization-wide contracts

Business economics

What drives the business
Moving from pilots to enterprise rollouts drives scale. Contracted ARR and live ARR are distinct measures.[1]

Leadership & functional coverage

Selected leaders supported by the linked sources; dated appointments retain their source context. This is not a complete org chart. Advisory roles are labeled.

LeaderRoleFunction / context
Shiv RaoFounder & CEOCompany leadership[2]
San OoCTOTechnology · appointed May 2026[2]
Sagar SanghviCFOFinance · appointment January 2025[3]
Janie LeeVP, ProductProduct · announcement January 2026[4]
Brian WilsonChief Commercial OfficerCommercial · November 2025 source[5]

Dated financial disclosures

DateEvent
May 2025~$100M ARR[1]

Estimate. Revenue observation; separate from the financing date.

Jun 2025$5.3B reference valuation[1]

Series E reference

Sector comparison

Same vertical; different business models and reporting periods. Values are not directly comparable revenue multiples.

CompanyRevenue measureReference valuation
Abridge~$100M ARR

May 2025

$5.3B

Jun 2025

Devoted Health~$3.27B revenue

FY2024

$25B

Oct 2026

OpenEvidence~$300M run rate

July 2026

$15B

Sep 2026

Ro~$3.02B run rate

October 2026

$7B

Feb 2022

Commure~$105M ARR

March 2024

$7B

May 2026

Open research questions

  • ↗How quickly do contracted deployments convert into recurring revenue?

Sources & definitions

Financial history preserves the source’s measurement basis. ARR, annualized revenue, completed-year sales and transaction volume are distinct. Product economics are Plank analysis of the cited business model; open questions are not asserted findings.

  1. 1Sacra · company research and financial history
  2. 2Company · leadership directory or appointment
  3. 3Company · leadership directory or appointment
  4. 4Company · leadership directory or appointment
  5. 5Company · leadership directory or appointment